FDA Reform Bill Introduced Dec. 20 By Reps. Greenwood, Eshoo
This article was originally published in The Gray Sheet
Executive Summary
Device-related FDA reform legislation will be pending in the House when the 107th Congress returns for its second legislative session in January
You may also be interested in...
House Loses Medical Device Reform Architect To BIO
Rep. Jim Greenwood's (R-Penn.) experience drafting combination product legislation suggests BIO will be alert to shared opportunities in the biologics/device policy arena
House Loses Medical Device Reform Architect To BIO
Rep. Jim Greenwood's (R-Penn.) experience drafting combination product legislation suggests BIO will be alert to shared opportunities in the biologics/device policy arena
MDUFMA Addresses In Vitro Diagnostics, Combination Product Regulation
FDA will be required to report to Congress on Center for Biologics Evaluation & Research review times for in vitro diagnostics under the "Medical Device User Fee and Modernization Act" of 2002 (MDUFMA), which cleared the House Energy & Commerce Committee Oct. 2